Literature DB >> 9468037

The effect of androgen deprivation on malignant and benign prostate tissue.

P Guinan1, D Didomenico, J Brown, M Shaw, R Sharifi, V Ray, S Shott, M Rubenstein.   

Abstract

The purpose of this research was to describe the changes in marker expression and histologic morphology following androgen deprivation in malignant and benign human prostates. Fourteen patients receiving pre-radical prostatectomy total androgen deprivation had pre- and post-androgen deprivation evaluation of marker expression and histologic morphology (both malignant and benign). Marker expression was significantly reduced for serum (p < 0.0001) and tissue (p < 0.004) PSA as well as bcl-2 expression (p < 0.008). There were significant histologic increases in vacuolization (p < 0.001), pyknosis (p < 0.04), fibrosis (p < 0.01) and lymphocytic infiltration (p < 0.008) in the malignant tissue. There were significant increases in squamous metaplasia (p < 0.0002), fibrosis (p < 0.0005), basal cell hypertrophy (p < 0.0005) and lymphocytic infiltration (p < 0.0002) in the benign tissue. Androgen deprivation therapy produces significant changes in marker expression and morphology in prostate specimens. At times these iatrogenic changes can be confusing. Clinicians and pathologists must be aware of these changes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9468037     DOI: 10.1007/bf02989642

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland.

Authors:  X Zhang; M Colombel; A Raffo; R Buttyan
Journal:  Biochem Biophys Res Commun       Date:  1994-02-15       Impact factor: 3.575

2.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Authors:  G L Wright; C Haley; M L Beckett; P F Schellhammer
Journal:  Urol Oncol       Date:  1995 Jan-Feb       Impact factor: 3.498

3.  Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates.

Authors:  M Masai; H Sumiya; S Akimoto; R Yatani; C S Chang; S S Liao; J Shimazaki
Journal:  Prostate       Date:  1990       Impact factor: 4.104

4.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

Authors:  M S Soloway; R Sharifi; Z Wajsman; D McLeod; D P Wood; A Puras-Baez
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

5.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

Authors:  N M Navone; P Troncoso; L L Pisters; T L Goodrow; J L Palmer; W W Nichols; A C von Eschenbach; C J Conti
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

6.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

Authors:  M V Pilepich; J M Krall; M al-Sarraf; M J John; R L Doggett; W T Sause; C A Lawton; R A Abrams; M Rotman; P Rubin
Journal:  Urology       Date:  1995-04       Impact factor: 2.649

7.  Histopathological changes in androgen-deprived localized prostatic cancer. A study in total prostatectomy specimens.

Authors:  M Hellström; M Häggman; S Brändstedt; M de la Torre; K Pedersen; I Jarlsfeldt; H Wijkström; C Busch
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

8.  Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA).

Authors:  C Magi Galluzzi; R Montironi; I Giannulis; L Diamanti; M Scarpelli; G Muzzonigro; M Polito
Journal:  Pathol Res Pract       Date:  1993-12       Impact factor: 3.250

9.  Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.

Authors:  D M Smith; W M Murphy
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

10.  Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

Authors:  A Berner; J M Nesland; H Waehre; J Silde; S D Fosså
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more
  4 in total

Review 1.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

2.  The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.

Authors:  Lisa Ann Kraus; Shanti K Samuel; Steven M Schmid; Donald J Dykes; William R Waud; Marie Christine Bissery
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 3.  Sex-biased adaptive immune regulation in cancer development and therapy.

Authors:  Johanna M Schafer; Tong Xiao; Hyunwoo Kwon; Katharine Collier; Yuzhou Chang; Hany Abdel-Hafiz; Chelsea Bolyard; Dongjun Chung; Yuanquan Yang; Debasish Sundi; Qin Ma; Dan Theodorescu; Xue Li; Zihai Li
Journal:  iScience       Date:  2022-07-04

4.  Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Authors:  Hongjuan Zhao; Alan Thong; Rosalie Nolley; Stephen W Reese; Jennifer Santos; Alexandre Ingels; Donna M Peehl
Journal:  J Transl Med       Date:  2013-08-28       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.